Asthma

Dupilumab may improve disease severity in children with eosinophilic esophagitis (EoE).

Higher vaccination rates were associated with less prevalent asthmatic symptoms, but additional research is needed to confirm these findings.

In 2 different dose groups, the majority of patients with eosinophilic esophagitis aged 1 to 11 achieved histologic remission at week 16 compared with patients treated with placebo.

However, more research is needed to effectively integrate this biomarker into individualized asthma management strategies for pediatric patients.

The findings show that the largest gaps are among pediatric patients with persistent asthma.

Mice with asthma that were fed bread with Saccharomyces cerevisiae UFMG A-905 yeast showed reduced airway inflammation and decreased IL-5 and IL-13 concentrations, and effects increased when combined with microcapsules.

The findings also show that skin testing positivity for perennial allergens was higher in patients with childhood-onset asthma compared with those with adult-onset asthma.

The study results also found that exposure to tree canopy area may protect children from asthma development; however, efficacy decreased as weed pollen exposure increased.

Patients with undiagnosed asthma or COPD who received usual care from their primary providers were more likely to visit the hospital or specialists because of respiratory illness.

By improving health insurance coverage and cost of inhalers, such as out-of-pocket caps, access to care can be increased. Some companies are aiming to improve access by implementing price caps.

Adults who did not report past 3-day electronic nicotine delivery system use did not have an increased risk of asthma incidence.

A review of asthma guidelines, pharmacotherapy, and the role of the pharmacist.

The study estimates that over 40% of academic pulmonary and allergy providers have not adopted the Single Maintenance and Reliever Therapy combination method in their practices.

The findings demonstrated that daytime heat waves were associated with approximately 19% higher odds of asthma-related hospitalizations in children.

According to the investigators, these findings support the investigation of rilzabrutinib in patients with asthma in a phase 3 trial program.

Despite the finding, the authors suggest further research is done to better understand the mechanisms behind the interactions between asthma, sleep, and depression.

The continuation of tezepelumab showed stronger benefits after stopping treatment for 2 years and compared with placebo.

This study is the first to preliminarily show that a community pharmacist intervention can produce a positive effect on reducing SABA reliance and improvement of ICS adherence in patients with asthma.

SMART uses an ICS and a long-acting beta-2 agonist (LABA) product, giving patients 4 years and older with moderate to severe uncontrolled persistent asthma 1 inhaler for dual symptom relief.

With these findings contributing to the understanding of neighborhood-level asthma risks, the authors note next steps can involve identifying and addressing disparities.

Drug therapy workups may reveal candidates for immune therapy and provide chance for interventions.

The findings emphasize a need for guideline-based care delivery for patients with severe asthma, particularly for patients who are facing social disparities within health care.

The authors note that additional research needs to be conducted to confirm whether the findings are consistent in adult patients.

Investigators added that additional randomized trials are still needed to confirm the benefits of traditional Chinese medicine, either with or without conventional therapies.